M.D. Anderson Cancer Center: Early phase 1 study closed enrollment, 96 enrolled (Estrogen Receptor Negative, HER2/Neu Negative)
M.D. Anderson Cancer Center: Early phase 1 study closed enrollment, 96 enrolled (Estrogen Receptor Negative, HER2/Neu Negative). Its enrollment of 96 is above the median of 80 (56th percentile). Dated 29 days ago, it is in the active follow-up window. Score 30/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 96 · 56th percentile of 8,879 ClinicalTrialStartPulse records · 1.2x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer |
| NCT ID | NCT02744053 |
| Phase | Early phase 1 |
| Status | active not recruiting |
| Conditions | Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Triple-Negative Breast Carcinoma |
| Intervention types | procedure, other, radiation, drug |
| Target enrollment | 96 |
| Site countries | United States |
| Posted | 2016-04-20 |
| Planned start | 2016-11-07 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-07 |
| Last update posted | 2026-10-07 |
| enrollment percentile | 56th of 8,879 (median 80, 1.2x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch M.D. Anderson Cancer Center
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock M.D. Anderson Cancer Center + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-07
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: M.D. Anderson Cancer Center and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- M.D. Anderson Cancer Center's enrollment: 56th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
30 / 100 Score
- Enrollment closed: data management, monitoring and closeout ahead.
What is the ClinicalTrialStartPulse record for M.D. Anderson Cancer Center?
M.D. Anderson Cancer Center's Early phase 1 study (NCT02744053) in Estrogen Receptor Negative, first posted 2016-04-20: enrollment closed (active, not recruiting) (2026-10-07), in an update posted 2026-10-07.
How does M.D. Anderson Cancer Center compare to other ClinicalTrialStartPulse records?
Its enrollment of 96 sits in the upper half (56th percentile) of 8,879 records; the median is 80. It is 29 days old, still within a typical 45-day follow-up window. Its Score of 30/100 is modest; treat it as background rather than a priority.
M.D. Anderson Cancer Center vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| M.D. Anderson Cancer Center | US | 96 | 56th | 2026-10-07 |
| City of Hope Medical Center | US | 100 | 60th | 2026-11-03 |
| Yale University | US | 139 | 68th | 2026-11-02 |
| Rush University Medical Center | US | 140 | 68th | 2026-10-30 |
Related records
ClinicalTrialStartPulse: Early phase 1 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor M.D. Anderson Cancer Center and peer early phase 1 records
Get new ClinicalTrialStartPulse records like M.D. Anderson Cancer Center by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.